354
Views
29
CrossRef citations to date
0
Altmetric
Original Article

Application of biodegradable dendrigraft poly-l-lysine to a small interfering RNA delivery system

, , , , , , , , & show all
Pages 49-57 | Received 29 Jan 2016, Accepted 27 Apr 2016, Published online: 16 May 2016

References

  • Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2002;411:494–8.
  • Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapies. Nature 2009;391:426–33.
  • Seyhan AA. RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet 2001;130:583–605.
  • Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002–7.
  • Whitehead K, Langer R, Anderson D. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129–38.
  • Abbasi E, Aval SF, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett 2014;9:247–56.
  • Petit MW, Griffiths P, Ferruti P, Richardson SC. Poly(amidoamine) polymers: soluble linear amphiphilic drug-delivery systems for genes, proteins and oligonucleotides. Ther Deliv 2011;2:907–17.
  • Wang M, Hu H, Sun Y, et al. A pH-sensitive gene delivery system based on folic acid-PEG-chitosan - PAMAM-plasmid DNA complexes for cancer cell targeting. Biomaterials 2013;34:10120–32.
  • Zhou J, Wu J, Hafdi N, et al. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun 2006;22:2362–4.
  • Mukherjee SP, Byrne HJ. Polyamidoamine dendrimer nanoparticle cytotoxicity, oxidative stress, caspase activation and inflammatory response: experimental observation and numerical simulation. Nanomedicine 2013;9:202–11.
  • Malik N, Wiwattanapatapee R, Klopsch R, et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000;65:133–48.
  • Cottet H, Martin M, Papillaud A, et al. Determination of dendrigraft poly-L-lysine diffusion coefficients by Taylor dispersion analysis. Biomacromolecules 2007;8:3235–43.
  • Collet H, Souaid E, Cottet H, et al. An expeditious multigram-scale synthesis of lysine dendrigraft (DGL) polymers by aqueous N-carboxyanhydride polycondensation. Chemistry 2010;16:2309–16.
  • Hofman J, Buncek M, Haluza R, et al. In vitro transfection mediated by dendrigraft poly(L-lysines): the effect of structure and molecule size. Macromol Biosci 2013;13:167–76.
  • Tang M, Dong H, Li Y, Ren T. Harnessing the PEG-cleavable strategy to balance cytotoxicity, intracellular release and the therapeutic effect of dendrigraft poly-l-lysine for cancer gene therapy. J Mater Chem B 2016;4:1284–95.
  • Kurosaki T, Kitahara T, Fumoto S, et al. Ternary complexes of pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems. Biomaterials 2009;30:2846–53.
  • Ohsaki M, Okuda T, Wada A, et al. In vitro gene transfection using dendritic poly(L-lysine). Bioconjug Chem 2002;13:510–17.
  • Kodama Y, Nakamura T, Kurosaki T, et al. Biodegradable nanoparticles composed of dendrigraft poly-L-lysine for gene delivery. Eur J Pharm Biopharm 2014;87:472–9.
  • Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114:100–9.
  • Ballarín-González B, Howard KA. Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions. Adv Drug Deliv Rev 2012;64:1717–29.
  • Trubetskoy VS, Wong SC, Subbotin V, et al. Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery. Gene Ther 2003;10:261–71.
  • Schlegel A, Largeau C, Bigey P, et al. Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes. J Control Release 2011;152:393–401.
  • Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 2012;7:5577–91.
  • Prodhomme EJ, Tutt AL, Glennie MJ, Bugg TD. Multivalent conjugates of poly-gamma-D-glutamic acid from Bacillus licheniformis with antibody F(ab') and glycopeptide ligands. Bioconjug Chem 2003;14:1148–55.
  • Ye H, Jin L, Hu R, et al. Poly(gamma,L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 2006;27:5958–65.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.